Home › Funds › Yiheng Capital Management, L.P. › BIOA
Yiheng Capital Management, L.P. position in BIOA
BIOAGE LABS INC · Health Care
Yiheng Capital Management, L.P. reported holding 294,036 shares of BIOA (BIOAGE LABS INC) in its Q3 2026 13F filing — a position valued at US$2.1M, representing 0.81% of its reported portfolio and ranking #20 among its reported holdings. Yiheng Capital Management, L.P. has disclosed BIOA holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Yiheng Capital Management, L.P.'s BIOA position evolved
Yiheng Capital Management, L.P. first disclosed a stake in BIOA in Q2 2026 at 170,532 shares (US$4.2M). Across 2 filings, Yiheng Capital Management, L.P. increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 294,036 shares valued at US$2.1M — an increase of 123,504 shares quarter over quarter.. Notable position changes include a 72% increase in Q3 2026 (shares fell 22% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 170.53K | $4.18M | New |
| Q3 2026 | 294.04K | $2.08M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BIOA and 13F data
BIOA (BIOAGE LABS INC) is a Health Care company. 53 other funds we track also report a position in BIOA — the largest reported positions include a16z Capital Management, L.L.C. (US$79.2M), Cormorant Asset Management, LP (US$58.6M), Octagon Capital Advisors LP (US$42.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BIOA
- a16z Capital Management, L.L.C. 3.23M sh · $79.24M · Q2 2026
- Cormorant Asset Management, LP 2.39M sh · $58.59M · Q2 2026
- Octagon Capital Advisors LP 1.75M sh · $42.84M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 1.67M sh · $40.97M · Q2 2026
- MPM BioImpact LLC 1.67M sh · $40.87M · Q2 2026
- BRAIDWELL LP 1.03M sh · $25.32M · Q2 2026
- Sofinnova Investments, Inc. 2.29M sh · $16.26M · Q3 2026
- Sands Capital Alternatives, LLC 786.35K sh · $5.58M · Q3 2026
- SPHERA FUNDS MANAGEMENT LTD. 213.67K sh · $5.24M · Q2 2026
- Ikarian Capital, LLC 200.00K sh · $4.90M · Q2 2026
- Pivotal bioVenture Partners Investment Advisor LLC 653.37K sh · $4.63M · Q3 2026
- Squadron Capital Management LLC 155.00K sh · $3.80M · Q2 2026
More on Yiheng Capital Management, L.P.
FAQ
How long has Yiheng Capital Management, L.P. held BIOA?
Yiheng Capital Management, L.P. has disclosed BIOA holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Yiheng Capital Management, L.P.'s current position in BIOA?
As of Q3 2026, Yiheng Capital Management, L.P. holds 294.04K shares of BIOA (BIOAGE LABS INC), valued at $2.08M, representing 0.81% of its reported portfolio and ranking #20.
Has Yiheng Capital Management, L.P. been buying or selling BIOA?
In the latest 13F filing (Q3 2026), Yiheng Capital Management, L.P. increased its position in BIOA.
Which other funds hold BIOA?
Other major institutional holders of BIOA include a16z Capital Management, L.L.C., Cormorant Asset Management, LP, Octagon Capital Advisors LP, among 53 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.